Isokaempferide
CAS No. 1592-70-7
Isokaempferide ( )
Catalog No. M31379 CAS No. 1592-70-7
Isokaempferide shows hepatoprotective, antiproliferative, and anti-inflammatory effects, the anti-inflammatory effects can be explained, at least in part, by reducing neutrophil degranulation, myeloperoxidase activity, mediators as well as TNF-alpha secretion.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 414 | In Stock |
|
50MG | Get Quote | In Stock |
|
100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameIsokaempferide
-
NoteResearch use only, not for human use.
-
Brief DescriptionIsokaempferide shows hepatoprotective, antiproliferative, and anti-inflammatory effects, the anti-inflammatory effects can be explained, at least in part, by reducing neutrophil degranulation, myeloperoxidase activity, mediators as well as TNF-alpha secretion.
-
DescriptionIsokaempferide shows hepatoprotective, antiproliferative, and anti-inflammatory effects, the anti-inflammatory effects can be explained, at least in part, by reducing neutrophil degranulation, myeloperoxidase activity, mediators as well as TNF-alpha secretion. Isokaempferide is used as a bronchodilator, can induce relaxation of guinea-pig isolated trachea.
-
Synonyms
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1592-70-7
-
Formula Weight300.3
-
Molecular FormulaC16H12O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Halopemide
Halopemide is a potent inhibitor of PLD (IC50 = 220 and 310 nM for human PLD1 and PLD2). Halopemid is an antagonist of dopamine receptors. Halopemid can be used in psychotropic research.
-
Pronase E
Pronase E is a mixture of proteolytic enzymes that is obtained from Streptomyces griseus and could digest protein into individual amino acids.
-
CITCO
CITCO inhibits growth and expansion of brain tumour stem cells (BTSCs) and has an EC50 of 49?nM over pregnane X receptor (PXR), and no activity on other nuclear receptors.